---
categories: 
- Database
- Release
date: 2023-07-06
title: Database release
---
Added entries:
- (FDA) _BRCA1_ and _BRCA2_ somatic and germline variants and sensitivity to olaparib in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer. 
- (FDA) _BRCA1_ and _BRCA2_  germline variants and sensitivity to olaparib for patients with metastatic pancreatic adenocarcinoma. 
- (FDA) _BRCA1_ and _BRCA2_ germline variants and sensitivity to olaparib for the treatment of adult patients with HER2-negative high risk early breast cancer. 
- (FDA) _ATM_, _ATR_, _BRCA1_, _BRCA2_, _CDK12_, _CHEK2_, _FANCA_, _MLH1_, _MRE11A_, _NBN_, _PALB2_, and _RAD51C_ somatic variants and sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer.

Revised entries:
- (FDA) _BRCA1_ and _BRCA2_ germline variants and sensitivity to olaparib in breast cancer. Revised description to add additional approval details from FDA drug label.
